Genelux Corporation Common Stock (GNLX)
Healthcare
Biotechnology
3.00 $
+1.4%
vs. previous close
Closing price · As of: 3. Aug 2026
Genelux Corporation Common Stock (GNLX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Operating Cash Flow" came in at -6.1 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.4 | -3.4 | -6.9 | -4.4 | -6.8 | -5.7 | -4.3 | -5.4 | -7.1 | -6.6 | -6.2 | -6.1 | -26 | |
| 0.3 | 0.3 | 0.2 | 0.2 | 0.2 | -0.8 | 0.2 | 0.1 | -0.2 | 0.1 | 0.1 | -0.1 | 0.0 | |
| 0.3 | 0.5 | 1.6 | 1.8 | 1.3 | 1.2 | 1.4 | 1.4 | 1.3 | 2.3 | 0.8 | 1.4 | 5.8 | |
| 0.6 | – | – | – | – | – | – | – | – | – | – | – | – | |
| -1.0 | 1.0 | -2.0 | 0.6 | -1.7 | 1.1 | 2.9 | 0.5 | -1.2 | -1.4 | 1.0 | 1.1 | -0.5 | |
| 0.4 | 0.3 | 0.2 | 0.0 | 0.2 | 0.0 | 0.1 | 0.0 | 0.1 | 0.5 | 0.4 | 0.9 | 2.0 | |
| -0.4 | -0.3 | -14 | -1.7 | -17 | 4.0 | 6.7 | 3.5 | -2.7 | 4.7 | 6.6 | -8.5 | 0.1 | |
| 23 | – | – | – | – | – | – | – | – | – | – | – | – | |
| -0.2 | – | – | – | – | 0.0 | 0.0 | – | – | – | – | – | – | |
| 23 | 6.4 | 0.4 | 0.7 | 28 | 0.0 | 0.1 | 9.6 | 0.1 | 0.0 | 0.3 | 19 | 19 | |
| 17 | 2.7 | -20 | -5.4 | 3.8 | -1.8 | 2.5 | 7.6 | -9.7 | -1.9 | 0.6 | 3.9 | -6.9 | |
| -5.8 | -3.6 | -7.2 | -4.4 | -7.1 | -5.8 | -4.4 | -5.5 | -7.2 | -7.1 | -6.6 | -7.0 | -28 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.